Placental hemostasis and sterile inflammation: New insights into gestational vascular disease

Thrombosis Research

Volumn 151, Issue , 2017, Pages S30-S33

  Kohli, Shrey ^a   Isermann, Berend ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Antiplatelet therapy; Gestational vascular disease; Low grade inflammation; Placenta mediated complications; Platelets

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CRYOPYRIN; INFLAMMASOME; PURINERGIC RECEPTOR;

ARTICLE; EXOSOME; FEMALE; FIBRINOLYTIC THERAPY; GESTATIONAL VASCULAR DISEASE; HEMOSTASIS; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; PLACENTA DISORDER; PLACENTA FUNCTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; TROPHOBLAST; VASCULAR DISEASE; BLOOD; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; PATHOLOGY; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; THROMBOCYTE; VASCULAR DISEASES; VASCULARIZATION;

BLOOD PLATELETS; EXTRACELLULAR VESICLES; FEMALE; HEMOSTASIS; HUMANS; INFLAMMASOMES; INFLAMMATION; PLACENTA; PLATELET AGGREGATION INHIBITORS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; VASCULAR DISEASES;

EID: 85014154992     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(17)30063-4     Document Type: Article

References (57)

1. [1] Aharon, A., Brenner, B., Microparticles and pregnancy complications. Thromb Res 127:Suppl 3 (2011), S67–S71.
2. [2] Mor, G., et al. Inflammation and pregnancy: the role of the immune system at the implantation site. Ann N Y Acad Sci 1221 (2011), 80–87.
3. [3] Boij, R., et al. Biomarkers of coagulation, inflammation, and angiogenesis are independently associated with preeclampsia. Am J Reprod Immunol 68:3 (2012), 258–270.
4. [4] Abildgaard, U., Heimdal, K., Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. Eur J Obstet Gynecol Reprod Biol 166:2 (2013), 117–123.
5. [5] Huppertz, B., Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 51:4 (2008), 970–975.
6. [6] Hutt, R., et al. Increased platelet volume and aggregation precede the onset of preeclampsia. Obstet Gynecol 83:1 (1994), 146–149.
7. [7] Morrison, R., et al. Platelet behaviour in normal pregnancy, pregnancy complicated by essential hypertension and pregnancy-induced hypertension. Thromb Haemost 54:3 (1985), 607–611.
8. [8] Rabini, R.A., et al. Biochemical-morphological modifications of platelet membranes during pregnancy-induced hypertension. Exp Mol Pathol 63:3 (1995), 175–185.
9. [9] Hayashi, M., Kiumi, F., Mitsuya, K., Changes in platelet ATP secretion and aggregation during pregnancy and in preeclampsia. Am J Med Sci 318:2 (1999), 115–121.
10. [10] Offermanns, S., et al. Defective platelet activation in G alpha(q)-deficient mice. Nature 389:6647 (1997), 183–186.
11. [11] Palumbo, J.S., et al. Role of fibrinogen- and platelet-mediated hemostasis in mouse embryogenesis and reproduction. J Thromb Haemost 2:8 (2004), 1368–1379.
12. [12] Sood, R., et al. Fetal gene defects precipitate platelet-mediated pregnancy failure in factor V Leiden mothers. J Exp Med 204:5 (2007), 1049–1056.
13. [13] Isermann, B., et al. Tissue-restricted expression of thrombomodulin in the placenta rescues thrombomodulin-deficient mice from early lethality and reveals a secondary developmental block. Development 128:6 (2001), 827–838.
14. [14] Isermann, B., et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 9:3 (2003), 331–337.
15. [15] Li, W., et al. Extraembryonic expression of EPCR is essential for embryonic viability. Blood 106:8 (2005), 2716–2722.
16. [16] Guo, H., Callaway, J.B., Ting, J.P., Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 21:7 (2015), 677–687.
17. [17] Martinon, F., Tschopp, J., NLRs join TLRs as innate sensors of pathogens. Trends Immunol 26:8 (2005), 447–454.
18. [18] Dowling, J.K., O'Neill, L.A., Biochemical regulation of the inflammasome. Crit Rev Biochem Mol Biol 47:5 (2012), 424–443.
19. [19] Arend, W.P., Palmer, G., Gabay, C., IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 223 (2008), 20–38.
20. [20] Heneka, M.T., et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493:7434 (2013), 674–678.
21. [21] Shahzad, K., et al. Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int 87:1 (2015), 74–84.
22. [22] Tseng, W.A., et al. NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration. Invest Ophthalmol Vis Sci 54:1 (2013), 110–120.
23. [23] Kohli, S., et al. Maternal extracellular vesicles and platelets promote preeclampsia through inflammasome activation in embryonic trophoblast. Blood, 2016.
24. [24] Mulla, M.J., et al. A role for uric acid and the Nalp3 inflammasome in antiphospholipid antibody-induced IL-1beta production by human first trimester trophoblast. PLoS One, 8(6), 2013, e65237.
25. [24] Mulla, M.J., et al. A role for uric acid and the Nalp3 inflammasome in antiphospholipid antibody-induced IL-1beta production by human first trimester trophoblast. PLoS One, 8(6), 2013, e65237.
26. [25] Shirasuna, K., et al. Palmitic acid induces interleukin-1beta secretion via NLRP3 inflammasomes and inflammatory responses through ROS production in human placental cells. J Reprod Immunol 116 (2016), 104–112.
27. [26] Khan, R.N., Hay, D.P., A clear and present danger: inflammasomes DAMPing down disorders of pregnancy. Hum Reprod Update 21:3 (2015), 388–405.
28. [27] Murphy, M.S., Tayade, C., Smith, G.N., Evidence of inflammation and predisposition toward metabolic syndrome after pre-eclampsia. Pregnancy Hypertens 5:4 (2015), 354–358.
29. [28] Xie, F., et al. Toll-like receptors 2 and 4 and the cryopyrin inflammasome in normal pregnancy and pre-eclampsia. BJOG 117:1 (2010), 99–108.
30. [29] Hottz, E.D., et al. Inflammasome in platelets: allying coagulation and inflammation in infectious and sterile diseases?. Mediators Inflamm, 2015, 2015, 435783.
31. [30] Zaborowski, M.P., et al. Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study. Bioscience 65:8 (2015), 783–797.
32. [31] Tong, M., Chamley, L.W., Placental extracellular vesicles and feto-maternal communication. Cold Spring Harb Perspect Med, 5(3), 2015, a023028.
33. [32] Mitchell, M.D., et al. Placental exosomes in normal and complicated pregnancy. Am J Obstet Gynecol 213:4 Suppl (2015), S173–S181.
34. [33] Aharon, A., The role of extracellular vesicles in placental vascular complications. Thromb Res 135:Suppl 1 (2015), S23–S25.
35. [34] Essayagh, S., et al. Microparticles from apoptotic monocytes induce transient platelet recruitment and tissue factor expression by cultured human vascular endothelial cells via a redox-sensitive mechanism. Thromb Haemost 98:4 (2007), 831–837.
36. [35] Shomer, E., et al. Microvesicles of women with gestational hypertension and preeclampsia affect human trophoblast fate and endothelial function. Hypertension 62:5 (2013), 893–898.
37. [36] Aharon, A., et al. Microparticles bearing tissue factor and tissue factor pathway inhibitor in gestational vascular complications. J Thromb Haemost 7:6 (2009), 1047–1050.
38. [37] Laude, I., et al. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost 85:1 (2001), 18–21.
39. [38] Bretelle, F., et al. Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost 89:3 (2003), 486–492.
40. [39] Vanwijk, M.J., et al. Isolated microparticles, but not whole plasma, from women with preeclampsia impair endothelium-dependent relaxation in isolated myometrial arteries from healthy pregnant women. Am J Obstet Gynecol 187:6 (2002), 1686–1693.
41. [40] Marques, F.K., et al. Circulating microparticles in severe preeclampsia. Clin Chim Acta 414 (2012), 253–258.
42. [41] Tannetta, D.S., et al. Syncytiotrophoblast Extracellular Vesicles from Pre-Eclampsia Placentas Differentially Affect Platelet Function. PLoS One, 10(11), 2015, e0142538.
43. [42] Taylor, R.N., et al. Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. Semin Reprod Endocrinol 16:1 (1998), 17–31.
44. [43] Nadar, S., Lip, G.Y., Platelet activation in the hypertensive disorders of pregnancy. Expert Opin Investig Drugs 13:5 (2004), 523–529.
45. [44] Golebiewska, E.M., Poole, A.W., Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev 29:3 (2015), 153–162.
46. [45] Spaans, F., et al. Danger signals from ATP and adenosine in pregnancy and preeclampsia. Hypertension 63:6 (2014), 1154–1160.
47. [46] Koszalka, P., et al. Targeted disruption of cd73/ecto-5’-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ Res 95:8 (2004), 814–821.
48. [47] Faas, M.M., et al. Extracellular ATP induces albuminuria in pregnant rats. Nephrol Dial Transplant 25:8 (2010), 2468–2478.
49. [48] McRae, J.L., et al. Overexpression of CD39 protects in a mouse model of preeclampsia. Nephrology (Carlton) 18:5 (2013), 351–355.
50. [49] Magee, L.A., et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can 36:7 (2014), 575–576.
51. [50] Nelson-Piercy, C., Hazards of heparin: allergy, heparin-induced thrombocytopenia and osteoporosis. Baillieres Clin Obstet Gynaecol 11:3 (1997), 489–509.
52. [51] Omri, A., et al. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost 61:1 (1989), 55–56.
53. [52] Duley, L., et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev, 2, 2007, CD004659.
54. [53] Duley, L., et al. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ 322:7282 (2001), 329–333.
55. [54] Santiago-Diaz, P., et al. Platelet antiaggregants in pregnancy. Rev Esp Cardiol 62:10 (2009), 1197–1198.
56. [55] De Santis, M., et al. Clopidogrel treatment during pregnancy: a case report and a review of literature. Intern Med 50:16 (2011), 1769–1773.
57. [56] Patti, G., et al. Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A “state-of-the-art” paper. Eur Heart J 35:33 (2014), 2213–2223b.